ProQR Therapeutics (PRQR) Other Accumulated Expenses (2013 - 2023)

ProQR Therapeutics (PRQR) has reported Other Accumulated Expenses for 11 consecutive years, with $5.5 million the latest figure, recorded in Q3 2023.

• Quarterly Other Accumulated Expenses fell 64.85% year-over-year to $5.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $5.5 million (down 64.85% YoY) and the FY2022 annual result came in at $9.9 million, down 19.27% from the prior year.
• Other Accumulated Expenses climbed to $5.5 million in Q3 2023 per PRQR's latest filing, from $4.6 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PRQR reached as high as $15.6 million in Q3 2022 and fell as low as $9.5 in Q1 2019.
• A 5-year average of $7.7 million and a median of $8.1 million in 2020 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses soared 102897403.65% — and 2021, when it plunged 99.92%.
• Year by year, Other Accumulated Expenses stood at $10.0 million in 2019, then sank by 30.57% to $7.0 million in 2020, then soared by 75.87% to $12.2 million in 2021, then dropped by 19.27% to $9.9 million in 2022, then slumped by 44.58% to $5.5 million in 2023.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $5.5 million, $4.6 million, and $5.6 million for Q3 2023, Q2 2023, and Q1 2023 respectively.